Krystal Biotech delays registrational study to 2027 as FDA requests new patient-reported outcome scale

 

Krystal Biotech delays KB111 Hailey-Hailey registrational study to 2027 after FDA requests new patient-reported outcome scale

• KB111 study delay was disclosed during Krystal Biotech's Q1 2026 earnings call on Hailey-Hailey disease program.
• Krystal Biotech beat Q1 2026 estimates with non-GAAP EPS $1.83 and VYJUVEK revenue of $116.4M.

https://finviz.com/quote?t=KRYS&p=d